AbbVie (NYSE:ABBV) Shares Up 3% – What’s Next?

Shares of AbbVie Inc. (NYSE:ABBV) rose 3% on Thursday . The stock traded as high as $229.05 and last traded at $227.5660. Approximately 8,689,308 shares were traded during mid-day trading, an increase of 14% from the average daily volume of 7,633,555 shares. The stock had previously closed at $220.89.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 results and guidance beat expectations with record net sales and continued strength in immunology brands (Skyrizi, Rinvoq); management raised FY guidance, supporting outlook for durable cash flow and dividends. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Positive Sentiment: AbbVie completed a post‑marketing study for Rinvoq in Korea, adding real‑world data that supports label adoption and continued immunology growth — a commercial tailwind for Rinvoq uptake. AbbVie’s Korean Rinvoq Study Wraps Up, Bolstering Real-World Data for Immunology Growth
• Positive Sentiment: Sell‑side support: Cantor Fitzgerald and other bulls reiterated favorable ratings/price targets after the quarter, reinforcing investor confidence in growth and dividend stability. AbbVie Inc. (ABBV) Achieves Record Net Sales on Diversified Growth Platform
• Neutral Sentiment: Analyst coverage and reports (Argus and others) are reframing valuation assumptions — useful for investors but mix of views leaves near‑term direction dependent on execution. Analyst Report: AbbVie Inc
• Neutral Sentiment: Clinical pipeline updates (e.g., Phase 2 elezanumab in acute cervical spinal cord injury) are being monitored; progress could be meaningful long term but currently remains binary/uncertain. AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury: What Investors Should Watch
• Negative Sentiment: AbbVie sued HHS/CMS after Botox was selected for Medicare drug price negotiation under the Inflation Reduction Act — legal fight highlights risk to Botox pricing and potential revenue pressure if the selection stands. AbbVie sues US health agency over Botox price controls
• Negative Sentiment: Competitive pressure: J&J’s heavy TV ad spend for Tremfya could slow market share gains for Rinvoq and Skyrizi in certain dermatology/psoriasis segments. J&J’s Tremfya roars 2026 with massive TV ad spend, trailed by AbbVie’s Rinvoq and Skyrizi
• Negative Sentiment: Operational/pricing headwinds: reporting on Medicaid concessions and reshaped U.S. operations signals potential margin pressure in the near term even as company focuses on growth. AbbVie Reshapes U.S. Operations With Medicaid Concessions And Growth Focus

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. Morgan Stanley upped their price target on shares of AbbVie from $269.00 to $270.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. UBS Group lowered their price objective on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a research note on Thursday, February 5th. BMO Capital Markets reissued an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research note on Thursday, January 15th. Berenberg Bank set a $275.00 price target on AbbVie in a report on Tuesday, January 20th. Finally, JPMorgan Chase & Co. increased their price objective on AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $251.00.

AbbVie Trading Up 3.0%

The company has a market cap of $402.20 billion, a PE ratio of 96.43, a PEG ratio of 0.77 and a beta of 0.35. The stock has a 50 day moving average price of $223.45 and a 200 day moving average price of $220.35.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter in the prior year, the company earned $2.16 earnings per share. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Equities analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

Institutional Investors Weigh In On AbbVie

Hedge funds and other institutional investors have recently bought and sold shares of the business. Norges Bank bought a new position in AbbVie during the 4th quarter valued at approximately $5,865,055,000. Wellington Management Group LLP boosted its holdings in AbbVie by 457.4% in the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares in the last quarter. Capital World Investors increased its holdings in shares of AbbVie by 106.3% during the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock valued at $2,986,777,000 after acquiring an additional 6,736,161 shares in the last quarter. Laurel Wealth Advisors LLC increased its holdings in shares of AbbVie by 18,384.4% during the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after acquiring an additional 5,675,095 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of AbbVie by 10.4% in the 4th quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.